Ofichem Header Ofichem Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Amyris","sponsor":"Infectious Disease Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amyris Reports Pre-Clinical Data For COVID-19 RNA Vaccine Platform With Advantaged Manufacturing, Storage And Distribution Characteristics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Amyris","sponsor":"Infectious Disease Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amyris Achieves Promising in-vivo Results for Intranasal RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Amyris","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amyris and ImmunityBio Complete Joint Venture for Next Generation COVID-19 RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Amyris

    Menu

    Amyris

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Amyris

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amyris and ImmunityBio Complete Joint Venture for Next Generation COVID-19 RNA Vaccine

              Details:

              The ability to ‘mix and match’ vaccine platforms through this new joint venture and ImmunityBio’s multiple COVID vaccine platforms represents one of the most exciting approaches to ending COVID-19 including hAd5 S+N.

              Lead Product(s): hAd5 S+N

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: ImmunityBio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amyris

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amyris Achieves Promising in-vivo Results for Intranasal RNA Vaccine

              Details:

              The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu.

              Lead Product(s): RNA Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Vaccine

              Partner/Sponsor/Collaborator: Infectious Disease Research Institute

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amyris

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amyris Reports Pre-Clinical Data For COVID-19 RNA Vaccine Platform With Advantaged Manufacturing, Storage And Distribution Characteristics

              Details:

              Preliminary data from a pre-clinical study of IDRI's Nanostructured Lipid Carrier (NLC) vaccine platform demonstrated a significant level of antibody production against the COVID-19 spike protein using a self-adjuvanting RNA vaccine.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Vaccine

              Partner/Sponsor/Collaborator: Infectious Disease Research Institute

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY